A complex pattern of neurological dysfunctions with generalized seizures and visual allucinations, but without focal signs, suddenly arose 20 days after an unrelated bone marrow transplant for chronic myelogenous leukemia (CML) in a 13-year-old girl, accompanied by signs of acute skin graft-versus-host disease (GVHD). Magnetic resonance imaging (MRI) revealed multiple bilateral foci of signal abnormalities, which were exclusively localized in the grey matter, sparing the white. Extensive microbiological and virological assays of cerebrospinal fluid (CSF) allowed the identification of HHV-6, variant A, DNA. Further progression of both neurological alterations and of skin and gut GVHD led to a fatal outcome 2 weeks later. A retrospective analysis of both the recipient and donor mononuclear cell suspensions supported the hypothesis that HHV-6 had been acquired from the donor with the bone marrow graft. This report suggests a pathogenetic role of HHV-6 in viral encephalitis in immunocompromised bone marrow transplant (BMT) recipients, and its possible association with GVHD.
Human herpesvirus type 6 (HHV-6) infects children early in life causing roseola infantum (exanthema subitum) and febrile illnesses. Although the infection is normally mild, a small proportion of patients develop severe complications including encephalitis. 1 Thereafter, the virus persists lifelong in the organism, and HHV-6 DNA may be detected in peripheral blood mononuclear cells and saliva. 2 Like other herpesviruses, HHV-6 can reactivate in immunocompromised subjects. Rise in HHV-6 antibody has been shown to occur during the course of kidney and liver transplantation. With regard to bone marrow transplantation (BMT), HHV-6 has been cultured from respiratory tract secretions in patients with interstitial pneumonitis. 3 In both BMT and AIDS patients with encephalitis, HHV-6 antigens have been detected in astrocytes 4,5 supporting a causative role for HHV-6 encephalitis.
In this report we describe a case of fatal HHV-6 encephalitis in an unrelated BMT patient, in whom the diagnosis was made by PCR analysis of cerebrospinal fluid (CSF). Furthermore, evidence is presented supporting the possibility that the virus was acquired from the unrelated donor with the bone marrow inoculum.
Case report
A 13-year-old girl was diagnosed with Philadelphia-positive chronic myelogenous leukemia (CML) in July 1993. At diagnosis she was treated with hydroxyurea and interferon, and lacking an HLA-identical sibling, she was referred to our Unit and a search for an unrelated donor was undertaken. After 1020 days, a partially matched donor, 1 antigen mismatched (DRB1), was identified. In October 1996 the patient was admitted to the BMT Unit. After conditioning with ifTBI (11 × 1.2 cGy) and cyclophosphamide (120 mg/kg), she received 1.76 × 10 8 nucleated cells/kg body weight. GVHD prophylaxis consisted of CYA and 'short' MTX plus horse anti-lymphocyte globulin. As antimicrobial prophylaxis, the patient received acyclovir 500 mg/m 2 × 3/day, ciprofloxacin, itraconazole and mitronidazole for gut decontamination, and hyperimmune immunoglobulin, 200 mg/kg body weight/weekly. Filgrastim was administered after the transplant. The immediate post-BMT period was complicated by grade II mucositis and fever 38-39°C which appeared on day +11 and persisted until day +18. Repeated blood and urine cultures were all negative, and broad-spectrum antimicrobials (meropenem, amikacine, teicoplanine and fluconazole) were initiated empirically. The first signs of engraftment appeared, with an ANC of 200/l on day +18. On day +20 her clinical status changed dramatically when focal seizures occurred (visual allucinations followed by left hemiclonic convulsions) accompanied by fever (39.2°C). Neurological examination and CT scan were normal. EEG showed a state of moderate somnolence without focal or paroxysmal abnormalities. Control of seizures was effected with diazepam and phenobarbital (150 mg/day). The ANC was 1800/l, platelets 60 000/l, LDH 1120, total bilirubin 0.9, haptoglobin 7 and no schistocytes were detectable in blood smears; blood levels of cyclosporine were within the therapeutic range. The day after, a skin infiltrate suggestive of GVHD arose; the diagnosis was confirmed by skin biopsy. Grade III GVHD was subsequently diagnosed and highdose methylprednisolone (10 mg/kg b.w.) was started. On day +22 she became apyrexial, the neurological examination was normal, and the skin rash resolved with improvement of the general status. On day +24, the skin rash appeared again, and the dosage of methylprednisolone was doubled. The seizures recurred and became increasingly frequent. Diazepam i.v. was ineffective, but phenytoin infusions (250 mg every 12 h) resulted in control of seizures. The interictal EEG showed periodic discharges of sharp waves in the left hemisphere at intervals of 1-1.5 s (Figure 1a) . The patient was slightly confused and neurological examination revealed no focal motor, sensory or Although marred by movement artifacts, FSE-FLAIR sequences (3) were more sensitive than conventional SE PDW and T2W sequences (1, 2) in revealing multiple, cortical lesions at the level of both calcarine fissures. On post-contrast scan (4), lack of lesion enhancement at the same level is demonstrated. cerebellar signs. Magnetic resonance imaging (MRI) showed multiple, bilateral and symmetrical foci of signal abnormality involving the cortical grey matter of the frontal, temporo-parietal and occipital lobes. Lesions were confluent at the level of both occipital and temporo-parietal lobes. Foci of signal alteration were also detected in the cerebellar hemispheres. However, on the post-contrast scan (0.1 mmol/kg Gd-DTPA i.v.), no lesions or meningeal enhancement were observed (Figure 1b) . A lumbar puncture was performed. Analysis of the CSF revealed an absence of white cells; the glucose level was 63 mg per deciliter and total protein 0.26 per deciliter. The albumin ratio (liquor/serum) was Ͻ0.004. Microbiological assays of the CSF were performed for bacteria, M. tuberculosis, cryptococcus, and for viruses (HSV, CMV, EBV, BKV, JCV, parvovirus B-19 and HHV-6). Acyclovir was discontinued and foscarnet was started on day +25. The neurological signs and general status of the patient remained unchanged, and an MRI performed on day +29 showed unmodified findings on both the plain and post-contrast examination; no brain atrophy was detected. On day +33 she deteriorated with a high fever, skin rash, diarrhea and progressive stupor and coma, until death occurred on day +35; autopsy was refused. On day +33 HHV-6 DNA was identified in the CSF by nested PCR assay; restriction endonuclease analysis 6 of the amplified DNA fragment identified HHV-6 variant A. Gancyclovir was added to the foscarnet in the hope of increasing the efficacy of the antiviral therapy.
After the patient's death, blood samples of both the donor and recipient were retrospectively analyzed for HHV-6 by PCR. Cells collected from the recipient before BMT were negative for HHV-6; however, cells from the donor were positive for HHV6 variant A, suggesting possible transmission of the virus from the donor (Figure 2a  and b) .
Discussion
HHV-6 has been isolated from peripheral blood mononuclear cells or from oral lavage fluid or urine in 40-60% of patients undergoing BMT, [7] [8] [9] while an increase in the antibody titer occurs in about 27%. However, serious diseases associated with HHV-6 such as pneumonitis 3 or encephalitis 4,10 are rarely described. This report provides further evidence that HHV-6 is able to infect the central nervous system (CNS) in BMT recipients. Clinical and laboratory data support the hypothesis that the causative agent of the acute encephalitis seen in our patient was HHV-6; and HHV-6 DNA has also been detected by PCR in a proportion of non-immunocompromised patients with focal encephalitis. 11 The neurological status was characterized by focal seizures and confusion, and the EEG showed periodic sharp waves with a temporal predominance, suggestive of herpetic encephalitis. MRI showed both selective and multifocal involvement of the cortical grey matter with a partially confluent asymmetrical pattern at the level of the frontal and occipital lobes, together with a lack of meningeal enhancement, strongly suggesting a viral aetiology. While the MRI and pathological pictures of herpes simplex (HSV-II) encephalitis are well described, reports of HHV-6 infection of the CNS are scanty. In the case reported by Drobyski et al 4 pathological lesions were demonstrated in both the hemispheric white matter and the cortical grey matter of the temporal lobes in the absence of CT and MRI lesions, while HHV-6 antigens were detected on post-mortem examination in both glial (astrocytes) and neurons. In contrast, in our case the MRI demonstrated diffuse involvement of the grey matter, particularly evident in FLAIR sequences. Selective cortical involvement allowed us to exclude progressive multifocal leukoencephalitis, subacute sclerosing panencephalitis and progressive rubella panencephalitis which may present with similar clinical findings. Both non-inflammatory vasculopathy and vasculitis of the brain vessels can complicate herpes virus infection in immunocompromised patients in the absence of systemic symptoms. In our case, MRI lesions did not show a vascular distribution, and the lack of hemorragic signs as well as of lesion enhancement on post-contrast MRI scans did not support the hypothesis of infective small vessel vasculitis.
PCR analysis of the CSF was positive for HHV-6 DNA and restriction analysis of the amplified DNA fragment revealed HHV-6 variant A. Detection of herpes virus DNA by PCR recently became the first-line diagnostic test for viral infections of the CNS 12 and is superior to brain biopsy for the diagnosis of herpes simplex encephalitis; 13 therefore, PCR positivity can be considered diagnostic of the disease. In this case HHV-6 variant A was detected, while in BMT patients a prevalence of variant B has been observed as expression of virus reactivation. 8 Furthermore, the fact that the same HHV-6 strain was detected in the donor cells strongly suggests transmission of the infection from the donor, although information concerning the immune status of the patient before BMT was unfortunately lacking. Thus, the possibility of endogeneous reactivation could not be excluded with certainty. In this case, the encephalitis occurred along with GVHD grade III, and it is possible that the HHV-6 infection synergistically enhanced immune reaction, resulting in the clinically severe GVHD. 14 In conclusion, this case stresses the emerging role of HHV-6 in the bone marrow transplant setting and its possible relationships with GVHD. MRI and PCR analysis of CSF proved to be very useful in making the diagnosis. Finally, the possibility of transmission of infection from donor to recipient emphasizes the importance of adding HHV-6 markers to the work-up for marrow donors.
